A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) (opens ClinicalTrials.gov)
- Sponsor
- Eli Lilly and Company
- Enrolment
- 510
- Started
- 2024-04-29
- Last update
- 2026-11-04
Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions: LY3650150, Placebo, Standard therapy for INCS